Challenges assessing clinical endpoints in early Huntington disease
- 作者Jane S. Paulsen; Chiachi Wang; Kevin Duff; Roger Barker; Martha Nance; Leigh Beglinger; David Moser; Janet K. Williams; Sheila Simpson; Douglas Langbehn; Daniel P. van Kammen
- 卷第25卷
- 期第15期
- 印刷ISSN0885-3185
- 电子ISSN1531-8257
- 文件大小99.78KB
- 发表时间2010
- DOI10.1002/mds.23337
- 页码2595-2603
Advances in clinical trials for movement disordersKieburtz, Karl; Olanow, C. Warren · Movement Disorders · 2015
Initiating levodopa therapy for Parkinson's diseaseOlanow, C. Warren; Kieburtz, Karl; Stocchi, Fabrizio · Movement Disorders · 2014
Huntington's disease: Current and future therapeutic prospectsKieburtz, Karl; Reilmann, Ralf; Olanow, C. Warren · Movement Disorders · 2018
Milestones in movement disorders clinical trials: Advances and landmark studiesC. Warren Olanow; Kathryn B. Wunderle; Karl Kieburtz · 2011
Why have we failed to achieve neuroprotection in Parkinson's disease?C. Warren Olanow; Karl Kieburtz; Anthony H. V. Schapira · 2008
Adverse event reporting in clinical trials in Parkinson's Disease: Time for changeOlanow, C. Warren; Kenney, Christopher; Bandak, Stephen; Kieburtz, Karl D. · Movement Disorders · 2018
Translational experimental therapeutics: The translation of laboratory-based discovery into disease-related therapyKarl Kieburtz; C. Warren Olanow · 2007